Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2024
>
Astellas and Sangamo sign capsid deal for neurological diseases
Astellas and Sangamo sign capsid deal for neurological diseases
Read also
Merck KGaA
Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership
FDA Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC
FDA Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC
ALS oral therapy
ALS oral therapy slows disease progression in preclinical testing
Alvotech and Advanz
Alvotech and Advanz announce EC approval for Gobivaz biosimilar
